Andere Sprachen Qiagen N.V. Xetra

Aktien

A400D5

NL0015001WM6

QIA

Markt geschlossen - Xetra Andere Börsenplätze 17:35:19 26.04.2024			% 5 Tage	% 1. Jan.
38.76 ^EUR	+2.16%		+3.44%	-4.58%

26.04.	TAGESVORSCHAU: Termine am 29. April 2024	DP
26.04.	WOCHENVORSCHAU: Termine bis 10. Mai 2024	DP

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Qiagen N : 2023 Annual Report 2023 IFRS Annual Report	25.04.
QIAGEN expands tuberculosis portfolio with new NGS Panel to support real-time surveillance and combat antimicrobial resistance	24.04.
QIAGEN N.V. Announces Launch of QIAseq xHYB Mycobacterium Biotechnology Panel for Research Use	24.04.
European Equities Close Higher in Monday Trading; EC Probes TikTok Over Possible DSA Violations	22.04.
QIAGEN N.V. to release results for Q1 2024 and hold webcast	09.04.
Qiagen N : launches new solution for screening of sexual assault forensic casework samples	04.04.
QIAGEN strengthens its portfolio for cancer research, showcasing latest product launches at AACR Annual Meeting 2024	03.04.
Qiagen N.V. Strengthens Its Portfolio for Cancer Research, Showcases Latest Product Launches At AACR Annual Meeting 2024	03.04.
Mybio Are the New Exclusive Partner for Qiagen in Ireland & Northern Ireland	27.03.
QIAGEN introduces QIAstat-Dx Analyzer 2.0 with remote test results access, enhancing collaboration across healthcare system	25.03.
QIAGEN Introduces QIAstat-Dx Analyzer 2.0 with Remote Test Results Access, Enhancing Collaboration Across Healthcare System	25.03.
Qiagen Teams Up With Physicians Association for Tuberculosis Screening Program	18.03.
QIAGEN partners with International Panel Physicians Association to increase awareness of tuberculosis screening requirements	18.03.
Qiagen N : Virtual Exane Conference Investor Introduction	12.03.
Qiagen N : TD Cowen Healthcare Conference March 5-6 Investor Introduction	12.03.
QIAGEN announces Form 20-F annual report filing for 2023 results	11.03.
For the UK: QIAGEN Ltd statement about the Modern Slavery Act 2015 for 2024	06.03.
QIAGEN launches AI-derived biomedical knowledge base to accelerate data-driven drug discovery	27.02.
QIAGEN earns ACT Label for new eco-friendlier QIAwave products and achieves first My Green Lab Platinum certification	27.02.
Qiagen N : Share buyback program initiated in 2024 2024 Federal-8937 Report of Organizational Actions Affecting Basis of Securities (SSBB)_RS signed	21.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Schlagzeilen

QIAGEN : In line Q4; Routine-Geschäftsaussichten bleiben intakt

Am 07. Februar 2024 um 16:30 Uhr